The fourth quarter earnings season has just begun. Some companies manage to consistently surprise the market with positive earnings reports. [...]
Gilead is a great company and stock, but expectations are high and outperformance in 2013 will be tough.
Gilead acquires YM Bio for $510 million in cash to grow its cancer drug pipeline.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.